Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study

Key Points

• The aim is to evaluate the effectiveness of anti-CD19 CAR T-cell therapy in patients with relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.
• Conducted a multicenter retrospective analysis
• Included patients with relapsed or refractory leukemia
• Assessed outcomes following anti-CD19 CAR T-cell therapy
• Observed significant responses in a subset of patients
• Demonstrated potential benefits in survival rates
• Highlighted the therapy's role in treatment-resistant cases